Elevating the corporate brand
Since 2004, IXICO Limited has developed innovative technologies for the research and treatment of serious neurological diseases, like dementia. They are recognised as having the best neuro-imaging expertise in the neuro-degeneration field and had a strong neuroscience brand within the pharmaceutical and academic research sectors.IXICO approached KISS to pitch for a fast track marketing communications campaign around their intention to list on AIM and the commercialisation of their first product into the healthcare sector. This represented a major opportunity to elevate IXICO’s corporate position and to drive a major step change in their business. KISS approached the challenge posed by IXICO with a tried and tested staged strategic process.
A concise brand articulation workshop helped IXICO define and express their corporate brand. KISS then designed and developed a fully responsive website which features a powerful CMS, a unique social media feed and as part of the AIM listing the site has been integrated with London Stock Exchange API to show up to date stock news and share prices. In tandem with the corporate brand work, KISS began work on the new dementia diagnosis product. This included creating a name, logo and brand identity, sales collateral and a web site which launched early in December 2013.
Rapidly following the launch of the new website, IXICO announced that it had been acquired by Phytopharm Plc and that Phytopharm would change its name to IXICO plc. In addition, the combined business was admitted to the Alternative Investment Market (“AIM”) of the London Stock Exchange. KISS continues to work with IXICO across a number of projects in an integrated capacity from marketing collateral to SEO, video production and digital.
“We chose KISS as the agency has a solid reputation in the science and technology sector and experience of working with businesses looking for significant growth.”
Kate McLeish, VP of Technology
View the site